STAT1 and neoplasm: IL-18 may confer protection against colitis-associated inflammation [113,114] and neoplasia [109,111] by modulating the permeability of the intestinal epithelium [113,114], the production of antimicrobial peptides [85], and the activation levels of the tumor suppressors IFN-γ and STAT1 [109].